Price Target Changed • May 19
Price target decreased by 11% to UK£0.13 Down from UK£0.15, the current price target is provided by 1 analyst. New target price is 97% above last closing price of UK£0.068. Stock is down 0.7% over the past year. The company posted a net loss per share of UK£0.032 last year. Recent Insider Transactions • Mar 15
Co-Founder & Executive Chairperson recently bought UK£232k worth of stock On the 12th of March, James Mellon bought around 3m shares on-market at roughly UK£0.07 per share. This transaction amounted to 34% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of UK£374k worth in shares. Recent Insider Transactions • Feb 26
Co-Founder & Executive Chairperson recently bought UK£66k worth of stock On the 25th of February, James Mellon bought around 990k shares on-market at roughly UK£0.066 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of UK£103k worth in shares. Annuncio • Dec 30
Agronomics Limited, Annual General Meeting, Feb 13, 2026 Agronomics Limited, Annual General Meeting, Feb 13, 2026. Location: the sanderson suite, claremont hotel, loch promenade, douglas im1 2lx Isle of Man Buy Or Sell Opportunity • Oct 07
Now 21% overvalued Over the last 90 days, the stock has fallen 30% to UK£0.061. The fair value is estimated to be UK£0.05, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 61% over the last 3 years. Meanwhile, the company became loss making. New Risk • Sep 30
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 8.1% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Market cap is less than US$100m (UK£63.6m market cap, or US$85.5m). New Risk • Aug 08
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: UK£73.7m (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 8.1% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (UK£73.7m market cap, or US$99.1m). Buy Or Sell Opportunity • Jul 07
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 27% to UK£0.076. The fair value is estimated to be UK£0.062, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 61% over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Apr 23
Now 23% undervalued Over the last 90 days, the stock has risen 53% to UK£0.058. The fair value is estimated to be UK£0.075, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 61% over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Apr 03
Now 21% undervalued Over the last 90 days, the stock has risen 55% to UK£0.059. The fair value is estimated to be UK£0.075, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 61% over the last 3 years. Meanwhile, the company became loss making. New Risk • Mar 14
New major risk - Revenue and earnings growth Earnings have declined by 8.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 8.1% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (UK£69.1m market cap, or US$89.4m). Price Target Changed • Jan 30
Price target decreased by 7.1% to UK£0.16 Down from UK£0.17, the current price target is an average from 2 analysts. New target price is 310% above last closing price of UK£0.038. Stock is down 62% over the past year. The company posted a net loss per share of UK£0.011 last year. Price Target Changed • Jan 22
Price target decreased by 9.3% to UK£0.17 Down from UK£0.18, the current price target is an average from 2 analysts. New target price is 330% above last closing price of UK£0.038. Stock is down 62% over the past year. The company posted a net loss per share of UK£0.011 last year. Annuncio • Dec 28
Agronomics Limited, Annual General Meeting, Feb 07, 2025 Agronomics Limited, Annual General Meeting, Feb 07, 2025. Location: the sanderson suite, claremont hotel, loch promenade, im1 2lx, douglas Isle of Man New Risk • Dec 25
New major risk - Revenue size The company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Market cap is less than US$100m (UK£38.6m market cap, or US$48.5m). New Risk • Dec 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Share price has been volatile over the past 3 months (7.5% average weekly change). Profit margins are more than 30% lower than last year (31% net profit margin). Market cap is less than US$100m (UK£45.4m market cap, or US$57.9m). Recent Insider Transactions • Oct 15
Co-Founder & Executive Chairperson recently bought UK£97k worth of stock On the 7th of October, James Mellon bought around 2m shares on-market at roughly UK£0.048 per share. This transaction amounted to 43% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of UK£146k worth in shares. New Risk • Sep 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Profit margins are more than 30% lower than last year (31% net profit margin). Market cap is less than US$100m (UK£57.5m market cap, or US$75.6m). New Risk • May 29
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: UK£76.7m (US$97.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (31% net profit margin). Market cap is less than US$100m (UK£76.7m market cap, or US$97.5m). Buy Or Sell Opportunity • May 10
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 14% to UK£0.087. The fair value is estimated to be UK£0.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 41% over the last 3 years. Meanwhile, the company has become profitable. New Risk • Apr 15
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: UK£75.7m (US$94.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (31% net profit margin). Market cap is less than US$100m (UK£75.7m market cap, or US$94.2m). Buy Or Sell Opportunity • Mar 19
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 4.5% to UK£0.09. The fair value is estimated to be UK£0.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 41% over the last 3 years. Meanwhile, the company has become profitable. Annuncio • Mar 15
Umami Meats Pte. Ltd. acquired Shiok Meats Pte. Ltd. from Agronomics Limited (AIM:ANIC) and others. Umami Meats Pte. Ltd. acquired Shiok Meats Pte. Ltd. from Agronomics Limited (AIM:ANIC) and others on March 13, 2024. Umami acquired Shiok Meats in share-for-share transaction. As a result of this transaction, Agronomics now holds an equity ownership of 0.71% in UMAMI Bioworks on a fully diluted basis. Subject to audit, this position will be carried forward at a book value of £0.378 million. James Biddle and Roland Cornish of Beaumont Cornish Limited acted as Financial advisor in transaction.
Umami Meats Pte. Ltd. completed the acquisition of Shiok Meats Pte. Ltd. from Agronomics Limited (AIM:ANIC) and others on March 13, 2024 Buy Or Sell Opportunity • Mar 04
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 13% to UK£0.09. The fair value is estimated to be UK£0.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 41% over the last 3 years. Meanwhile, the company has become profitable. New Risk • Feb 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Profit margins are more than 30% lower than last year (75% net profit margin). Annuncio • Jan 18
Agronomics Limited Announces IsraFirst Regulatory Approval for Cultivated Beef Agronomics Ltd. announced that the Israeli Ministry of Health (IMOH) has granted regulatory approval for the world's first commercial sale of cultivated beef. Agronomics would like to congratulate Aleph Farms on becoming the first company in the world to gain regulatory approval for its cultivated beef product after the IMOH issued a 'no questions' letter, which allows the company to commercialise its products in Israel. Aleph Farms has also filed for regulatory approval in Singapore, Switzerland, the UK and the US, and is advancing its applications in other markets. Agronomics is aware of multiple companies, including those within its portfolio, that are expecting regulatory approval for cultivated meat and seafood products across several markets. Meanwhile, Vow Food is in the middle of a consultation process after its cultured quail was cleared as safe to eat by Food Standards Australia and New Zealand in December 2023. These announcements follow Upside Foods and Good Meat, which received regulatory approval for their cultivated chicken products in the US last year. New Risk • Dec 27
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 75% Last year net profit margin: 130% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company. Annuncio • Dec 27
Agronomics Limited, Annual General Meeting, Feb 08, 2024 Agronomics Limited, Annual General Meeting, Feb 08, 2024, at 10:00 Coordinated Universal Time. Location: Sanderson Suite, Claremont Hotel, Loch Promenade Douglas Isle of Man Annuncio • Dec 14
Agronomics Limited appoints Jim Mellon as Executive Chairperson of the Board of Directors, 14 December 2023 Agronomics Limited announced that it has appointed Jim Mellon as Executive Chairperson of the Board of Directors, effective 14 December 2023. Jim Mellon, formerly an Executive Director, succeeds Richard Reed in the role of Chair, with Richard Reed continuing to serve as an Independent Non-Executive Director of the Board. Annuncio • Sep 23
Agronomics Limited (AIM:ANIC) announces an Equity Buyback for £3 million worth of its shares. Agronomics Limited (AIM:ANIC) announces a share repurchase program. Under the program, the company will repurchase up to £3 million worth of its shares. The maximum price to be paid for repurchase is the higher of the price of the last independent trade and the highest current independent purchase bid on the trading venue where the purchase is carried out and no share shall be bought back by the Company at a price per share higher than 75% of the last reported NAV Per Share published in the Company's most recent Quarterly NAV Statement. The purpose of the program is to reduce the share capital of the company. The repurchased shares will be cancelled unless used to cover obligations under share-based remuneration arrangements. The program will be valid till March 29, 2024. As of September 22, 2023, the company had 993,153,870 issued shares. New Risk • Aug 11
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company. Recent Insider Transactions • Mar 29
Executive Director recently bought UK£70k worth of stock On the 27th of March, James Mellon bought around 666k shares on-market at roughly UK£0.10 per share. This transaction amounted to 50% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought UK£75k more in shares than they have sold in the last 12 months. Annuncio • Dec 21
Agronomics Limited, Annual General Meeting, Feb 02, 2023 Agronomics Limited, Annual General Meeting, Feb 02, 2023, at 10:00 Coordinated Universal Time. Location: Sanderson Suite, Claremont Hotel Loch Promenade Douglas Isle of Man Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Non-Executive Director David Giampaolo was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Jun 19
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Non-Executive Director David Giampaolo was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annuncio • Jun 25
An unknown buyer acquire an unknown minority stake in Insilico Medicine, Inc. from Agronomics Limited (AIM:ANIC) for $0.67 million. An unknown buyer acquired an unknown minority stake in Insilico Medicine, Inc. from Agronomics Limited (AIM:ANIC) for $0.67 million on June 24, 2021. The remaining legacy positions in the portfolio continue to be monitored and will be sold down as opportunities arise. The proceeds will provide Agronomics with further funding for new and existing opportunities within the field of cellular agriculture.
An unknown buyer completed the acquisition of an unknown minority stake in Insilico Medicine, Inc. from Agronomics Limited (AIM:ANIC) on June 24, 2021. Annuncio • Dec 14
Agronomics Limited, Annual General Meeting, Feb 02, 2021 Agronomics Limited, Annual General Meeting, Feb 02, 2021, at 11:00 Coordinated Universal Time. Location: Sanderson Suite, Claremont Hotel Loch Promenade Douglas Isle of Man Annuncio • Jun 20
Agronomics Limited Initiates A Consultation Process with Shareholders Regarding A Possible De-Listing of the Company from the AIM Market The Board of Agronomics Limited confirmed on June 19, 2020 that, having carefully reviewed different funding options, it has initiated a consultation process with shareholders of the Company ("Shareholders") regarding a possible de-listing of the Company from the AIM Market. The Board believes the de-listing from AIM ("De-Listing") together with a tender offer (together the "Proposals"), would be in the best interests of the Company and Shareholders. Prior to convening any such general meeting, the Company has initiated a 14-day consultation process to establish the level of Shareholder support for the Proposals (the "Shareholder Consultation"). Following the Shareholder Consultation, if the Company does not have sufficient Shareholder support for the requisite resolutions relating to the Proposals to be passed at a general meeting, or is unable to satisfy the anticipated demand for the Tender Offer such that sufficient shareholder support for the Proposals can be achieved, the Company will not proceed with the Proposals. 
